Using incentive spirometry to help lung cancer patients during treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates whether using an incentive spirometer can reduce lung complications in patients with advanced lung cancer undergoing concurrent chemotherapy and radiation therapy. Participants will use the spirometer to encourage deep breathing multiple times an hour while awake, both during treatment and for up to three months afterward. The study aims to assess the impact of this non-pharmacological intervention on the incidence of pneumonitis and overall quality of life, with evaluations conducted at various intervals. By comparing outcomes, researchers hope to determine the effectiveness of incentive spirometry in improving patient well-being during and after cancer treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Confirmed diagnosis of advanced non-small-cell lung cancer
* Performance status (ECOG 0-1)
* Eligible for concurrent chemotherapy and radiation
* 18 years or older

Exclusion Criteria:

* Previous lung or thoracic surgery
* Enrollment in another pulmonary intervention trial
* Home oxygen usage prior to enrolment
* Radiological evidence of pleural effusion, pneumothorax, bullous emphysema, - or pneumonitis on staging imaging
* Presence of active respiratory tract infection
* Uncontrolled nausea and vomiting
* Prior exposure to drugs such as amiodarone, bleomycin, or immunotherapy
* Inability or unwillingness of individual to give written informed consent

Where it's running

• MD Anderson Cancer Center at Cooper
  Camden, New Jersey, United States Recruiting

Study contacts

• Study coordinator: Veli Bakalov, MD
• Email: bakalov-veli@cooperhealth.edu
• Phone: 856-735-6100

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Investigating HER3-DXd for advanced solid tumors

  This study is testing a new drug called HER3-DXd to see if it can safely help people with advanced solid tumors like melanoma, head and neck cancer, and gastric cancer who have already tried other treatments.

  Recruiting at 92 sites Phase 2 Daiichi Sankyo · Duarte, California and 95 other locations · NCT06172478

• Using a new imaging probe to detect tissue damage from radiation in lung and pancreatic cancer patients

  This study is testing a new imaging probe to see if it can help find tissue damage from radiation in lung and pancreatic cancer patients.

  Recruiting Phase 2 Massachusetts General Hospital · Boston, Massachusetts · NCT04485286

• ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden

  This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.

  Recruiting Tongji Hospital · Hubei, Wuhan · NCT07912190

• CR-002 study in adults with advanced solid tumors

  This trial tests CR-002 as a single therapy to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors

  Recruiting at 3 sites Phase 1/2 Crescent Biopharma, Inc. · Austin, Texas and 2 other locations · NCT07909031

• NSCLC biomarker study using tumor and blood samples to link genetics with prognosis and immunotherapy response

  Researchers will test tumor tissue and blood from about 300 NSCLC patients to find genomic and immune markers that predict prognosis and response to immunotherapy.

  Recruiting at 20 sites Hellenic Cooperative Oncology Group · Limassol and 19 other locations · NCT07900581

• Urine VOC Test to Detect Lung Cancer in Never Smokers

  A urine test that looks for volatile compounds is tested to see if it can help detect lung cancer in adults who have never smoked.

  Recruiting Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07871656

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.